Lixte Seeks Shareholder Approval for Expanded Stock Plan, Director Slate

TL;DR

**LIXT is asking shareholders to approve a massive 2,750,000 share increase to its stock incentive plan, signaling potential dilution and a need for strong talent incentives in a high-risk biotech play.**

AI Summary

Lixte Biotechnology Holdings, Inc. (LIXT) is holding its 2025 Annual Meeting of Stockholders on December 8, 2025, to address several key proposals. The company seeks to elect five director nominees and ratify the appointment of Weinberg & Company, P.A. as its independent registered public accounting firm for the fiscal year ending December 31, 2025. A significant proposal involves amending the 2020 Stock Incentive Plan to increase the number of shares issuable thereunder by 2,750,000 shares, bringing the total to 3,500,000 shares. This increase in the stock incentive plan could dilute existing shareholder value but is intended to attract and retain talent. The meeting will be entirely virtual, accessible via live webcast, with the record date for voting set as October 14, 2025, when 5,704,200 shares of common stock were outstanding. The company is utilizing SEC rules to provide proxy materials online, mailing a Notice of Internet Availability of Proxy Materials around October 29, 2025.

Why It Matters

For investors, the proposed increase of 2,750,000 shares in Lixte's 2020 Stock Incentive Plan to a total of 3,500,000 shares is a critical item, as it could lead to significant dilution of existing shareholder value. This move, while potentially beneficial for attracting and retaining key talent in the competitive biotech sector, directly impacts per-share earnings and ownership percentages. The election of five directors and the ratification of Weinberg & Company, P.A. as auditors are standard governance matters, but the stock plan expansion signals a strategic focus on incentivizing management and employees, which could be a double-edged sword for current shareholders. Investors should weigh the potential benefits of talent retention against the immediate dilution risk.

Risk Assessment

Risk Level: medium — The proposal to increase the 2020 Stock Incentive Plan by 2,750,000 shares, to a total of 3,500,000 shares, presents a medium risk of dilution for existing shareholders. While the filing does not provide specific financial performance metrics like revenue or net income, the substantial increase in potential share issuance for compensation could negatively impact per-share value if not offset by significant future growth or performance.

Analyst Insight

Investors should carefully review the implications of the proposed 2,750,000 share increase to the 2020 Stock Incentive Plan. Consider voting against this proposal if you are concerned about potential dilution without clear performance metrics or if you believe the current share count of 5,704,200 outstanding shares makes this increase disproportionately large.

Key Numbers

• 2,750,000 shares — Increase in 2020 Stock Incentive Plan (Proposed increase to the total shares available for issuance under the plan)
• 3,500,000 shares — Total shares in 2020 Stock Incentive Plan (New total if the amendment is approved, up from an unspecified prior amount)
• 5,704,200 shares — Common stock outstanding (Number of shares entitled to vote as of the October 14, 2025 record date)
• December 8, 2025 — Annual Meeting Date (Date of the 2025 Annual Meeting of Stockholders)
• October 14, 2025 — Record Date (Date for determining stockholders entitled to vote at the Annual Meeting)
• 5 — Director Nominees (Number of individuals proposed for election to the Board of Directors)

Key Players & Entities

• LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant for DEF 14A filing
• Weinberg & Company, P.A. (company) — Independent registered public accounting firm
• Geordan Pursglove (person) — Chairman of the Board
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for proxy materials
• The Nasdaq Capital Market (regulator) — Stock exchange where LIXT is listed
• Vstock LLC (company) — Company's transfer agent
• $2,750,000 (dollar_amount) — Increase in shares for 2020 Stock Incentive Plan (implied value)
• $3,500,000 (dollar_amount) — Total shares for 2020 Stock Incentive Plan (implied value)
• $5,704,200 (dollar_amount) — Shares of common stock outstanding on October 14, 2025 (implied value)

FAQ

Industry Context

Lixte Biotechnology Holdings, Inc. operates in the biotechnology sector, which is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. The industry is competitive, with companies focusing on developing novel therapeutics for unmet medical needs. Success often depends on clinical trial outcomes, intellectual property protection, and securing funding for ongoing research.

Regulatory Implications

As a biotechnology company, Lixte is subject to stringent regulations from bodies like the FDA. The proposed increase in the stock incentive plan, while intended for talent retention, could be scrutinized by investors for its potential dilutive effect. The company's reliance on SEC rules for proxy material distribution is standard practice but requires adherence to disclosure requirements.

What Investors Should Do

1. Review the proposed amendment to the 2020 Stock Incentive Plan.
2. Vote on the election of the five director nominees.
3. Confirm the ratification of Weinberg & Company, P.A. as the independent auditor.
4. Note the virtual format of the Annual Meeting.

Key Dates

• 2025-12-08: 2025 Annual Meeting of Stockholders — Key date for voting on director elections, auditor ratification, and stock incentive plan amendments.
• 2025-10-14: Record Date — Determines which stockholders are entitled to vote at the Annual Meeting. 5,704,200 shares of common stock were outstanding on this date.
• 2025-10-29: Mailing of Notice of Internet Availability of Proxy Materials — Informs stockholders how to access proxy materials online or request physical copies.

Glossary

DEF 14A

A proxy statement filing required by the SEC for companies holding annual meetings, containing information about matters to be voted on. (This document is the DEF 14A for Lixte Biotechnology Holdings, Inc.'s 2025 Annual Meeting.)

Proxy

A document authorizing someone to act for another, in this case, authorizing a representative to vote a stockholder's shares. (The company is soliciting proxies from stockholders for the Annual Meeting.)

2020 Stock Incentive Plan

A plan established in 2020 to grant stock options or other equity awards to employees, directors, and consultants. (A proposal to amend this plan to increase the number of issuable shares by 2,750,000 is a key item for stockholder vote.)

Street Name

Shares of a company held in an account at a broker, bank, or other financial institution on behalf of the beneficial owner. (Beneficial owners holding shares in street name will receive a Notice of Internet Availability of Proxy Materials.)

Year-Over-Year Comparison

This filing pertains to the 2025 Annual Meeting, and direct year-over-year comparisons of financial metrics like revenue, net income, or margins are not available within this proxy statement. The primary focus is on corporate governance matters, including director elections, auditor ratification, and proposed amendments to equity incentive plans, rather than a review of past financial performance.

Key Financial Figures

• $200 million — Based in Cancn, Mexico, he has led over $200 million in early and growth-stage investments a
• $3.5 billion — Candlebrook Capital and has raised over $3.5 billion for top-tier managers including Blackst

Filing Documents

• formdef14a.htm (DEF 14A) — 946KB
• formdef14a_001.jpg (GRAPHIC) — 337KB
• formdef14a_002.jpg (GRAPHIC) — 232KB
• 0001493152-25-019697.txt ( ) — 3134KB
• lixt-20241231.xsd (EX-101.SCH) — 6KB
• lixt-20241231_def.xml (EX-101.DEF) — 11KB
• lixt-20241231_lab.xml (EX-101.LAB) — 61KB
• lixt-20241231_pre.xml (EX-101.PRE) — 45KB
• formdef14a_htm.xml (XML) — 159KB

Business

Business 34 3 Lixte Biotechnology Holdings, Inc. 433 Plaza Real, Suite 275 Boca Raton, FL 33432 PROXY FOR 2025 ANNUAL MEETING OF STOCKHOLDERS December 8, 2025 INTRODUCTION The enclosed proxy is solicited by the Board of Directors (the "Board of Directors" or "Board") of Lixte Biotechnology Holdings, Inc. (the "Company"), in connection with the 2023 Annual Meeting of Stockholders (the "Annual Meeting") of the Company, to be held on December 8, 2025, at 10:00 a.m. Pacific Time via live webcast. To attend the Virtual Meeting, please register in advance at: https://meeting.vstocktransfer.com/LIXTEDEC25 . At the Annual Meeting, you will be asked to consider and vote upon the following matters: (1) To elect the five nominees for director named herein. (2) To ratify the appointment of Weinberg & Company, P.A. as the Company's independent registered public accounting firm for the (3) To approve a proposal to amend the Company's 2020 Stock Incentive Plan (the "2020 Plan") to increase the number of common shares issuable thereunder by 2,750,000 shares, to a total of 3,500,000 shares. (4) To authorize the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of one or more of the Proposals. (5) To transact other business that may properly come before the meeting and any postponement(s) or adjournment(s) thereof. The Board of Directors has fixed the close of business on October 14, 2025, as the record date (the "Record Date") for determining stockholders entitled to notice of and to vote at the Annual Meeting and any adjournment thereof. In accordance with rules and regulations adopted by the U.S. Securities and Exchange Commission (the "SEC"), we have elected to provide our beneficial owners and stockholders of record access to our proxy materials over the Internet. Beneficial owners are stockholders whose shares are hel

View Full Filing

View this DEF 14A filing on SEC EDGAR